Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 385 to 396 of 396 entries
Sorted by: Best Match Show Resources per page
Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma.

Journal of lipid research

Kovrov O, Landfors F, Saar-Kovrov V, Näslund U, Olivecrona G.
PMID: 34710432
J Lipid Res. 2021 Oct 26;63(1):100144. doi: 10.1016/j.jlr.2021.100144. Epub 2021 Oct 26.

LPL is a key player in plasma triglyceride metabolism. Consequently, LPL is regulated by several proteins during synthesis, folding, secretion, and transport to its site of action at the luminal side of capillaries, as well as during the catalytic...

Cite
Kovrov O, Landfors F, Saar-Kovrov V, et al. Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma. J Lipid Res. 2021;63(1):100144doi: 10.1016/j.jlr.2021.100144.
Kovrov, O., Landfors, F., Saar-Kovrov, V., Näslund, U., & Olivecrona, G. (2021). Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma. Journal of lipid research, 63(1), 100144. https://doi.org/10.1016/j.jlr.2021.100144
Kovrov, Oleg, et al. "Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma." Journal of lipid research vol. 63,1 (2021): 100144. doi: https://doi.org/10.1016/j.jlr.2021.100144
Kovrov O, Landfors F, Saar-Kovrov V, Näslund U, Olivecrona G. Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma. J Lipid Res. 2021 Oct 26;63(1):100144. doi: 10.1016/j.jlr.2021.100144. Epub 2021 Oct 26. PMID: 34710432.
Copy Download .nbib Format: NLM
Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia.

Annals of general psychiatry

Rao W, Meng X, Li K, Zhang Y, Zhang XY.
PMID: 34930329
Ann Gen Psychiatry. 2021 Dec 20;20(1):56. doi: 10.1186/s12991-021-00376-w.

BACKGROUND: The apolipoprotein E (ApoE) gene polymorphisms are correlated with blood lipid levels and several neuropsychiatric symptoms. Therefore, this study aimed to examine whether the ApoE rs429358 affected the development and clinical symptoms of schizophrenia and to explore the...

Cite
Rao W, Meng X, Li K, et al. Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia. Ann Gen Psychiatry. 2021;20(1):56doi: 10.1186/s12991-021-00376-w.
Rao, W., Meng, X., Li, K., Zhang, Y., & Zhang, X. Y. (2021). Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia. Annals of general psychiatry, 20(1), 56. https://doi.org/10.1186/s12991-021-00376-w
Rao, Wenwang, et al. "Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia." Annals of general psychiatry vol. 20,1 (2021): 56. doi: https://doi.org/10.1186/s12991-021-00376-w
Rao W, Meng X, Li K, Zhang Y, Zhang XY. Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia. Ann Gen Psychiatry. 2021 Dec 20;20(1):56. doi: 10.1186/s12991-021-00376-w. PMID: 34930329; PMCID: PMC8686343.
Copy Download .nbib Format: NLM
Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia.

Annals of general psychiatry

Rao W, Meng X, Li K, Zhang Y, Zhang XY.
PMID: 34930329
Ann Gen Psychiatry. 2021 Dec 20;20(1):56. doi: 10.1186/s12991-021-00376-w.

BACKGROUND: The apolipoprotein E (ApoE) gene polymorphisms are correlated with blood lipid levels and several neuropsychiatric symptoms. Therefore, this study aimed to examine whether the ApoE rs429358 affected the development and clinical symptoms of schizophrenia and to explore the...

Cite
Rao W, Meng X, Li K, et al. Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia. Ann Gen Psychiatry. 2021;20(1):56doi: 10.1186/s12991-021-00376-w.
Rao, W., Meng, X., Li, K., Zhang, Y., & Zhang, X. Y. (2021). Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia. Annals of general psychiatry, 20(1), 56. https://doi.org/10.1186/s12991-021-00376-w
Rao, Wenwang, et al. "Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia." Annals of general psychiatry vol. 20,1 (2021): 56. doi: https://doi.org/10.1186/s12991-021-00376-w
Rao W, Meng X, Li K, Zhang Y, Zhang XY. Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia. Ann Gen Psychiatry. 2021 Dec 20;20(1):56. doi: 10.1186/s12991-021-00376-w. PMID: 34930329.
Copy Download .nbib Format: NLM
Identification of blood-based biomarkers for diagnosis and prognosis of Parkinson's disease: A systematic review of proteomics studies.

Ageing research reviews

Chelliah SS, Bhuvanendran S, Magalingam KB, Kamarudin MNA, Radhakrishnan AK.
PMID: 34798300
Ageing Res Rev. 2021 Nov 16;73:101514. doi: 10.1016/j.arr.2021.101514. Epub 2021 Nov 16.

Parkinson's Disease (PD), a neurodegenerative disorder, is characterised by the loss of motor function and dopamine neurons. Therapeutic avenues remain a challenge due to lack of accuracy in early diagnosis, monitoring of disease progression and limited therapeutic options. Proteomic...

Cite
Chelliah SS, Bhuvanendran S, Magalingam KB, et al. Identification of blood-based biomarkers for diagnosis and prognosis of Parkinson's disease: A systematic review of proteomics studies. Ageing Res Rev. 2021;73:101514doi: 10.1016/j.arr.2021.101514.
Chelliah, S. S., Bhuvanendran, S., Magalingam, K. B., Kamarudin, M. N. A., & Radhakrishnan, A. K. (2021). Identification of blood-based biomarkers for diagnosis and prognosis of Parkinson's disease: A systematic review of proteomics studies. Ageing research reviews, 73101514. https://doi.org/10.1016/j.arr.2021.101514
Chelliah, Shalini Sundramurthi, et al. "Identification of blood-based biomarkers for diagnosis and prognosis of Parkinson's disease: A systematic review of proteomics studies." Ageing research reviews vol. 73 (2021): 101514. doi: https://doi.org/10.1016/j.arr.2021.101514
Chelliah SS, Bhuvanendran S, Magalingam KB, Kamarudin MNA, Radhakrishnan AK. Identification of blood-based biomarkers for diagnosis and prognosis of Parkinson's disease: A systematic review of proteomics studies. Ageing Res Rev. 2021 Nov 16;73:101514. doi: 10.1016/j.arr.2021.101514. Epub 2021 Nov 16. PMID: 34798300.
Copy Download .nbib Format: NLM
A systematic review and meta-analysis on the impact of oral vitamin E supplementation on apolipoproteins A1 and B100.

Clinical nutrition ESPEN

Hamedi-Kalajahi F, Zarezadeh M, Dehghani A, Musazadeh V, Kolahi A, Shabbidar S, Djafarian K.
PMID: 34857183
Clin Nutr ESPEN. 2021 Dec;46:106-114. doi: 10.1016/j.clnesp.2021.09.013. Epub 2021 Sep 29.

BACKGROUND AND AIM: Cardiovascular diseases (CVDs) are the number one cause of mortality worldwide. Apolipoprotein B (ApoB), apolipoprotein A1 (ApoA1), and ApoB/ApoA1 ratio are considered as predictors of CVD alongside with lipid profile. Evidence suggest that nutrients with antioxidant...

Cite
Hamedi-Kalajahi F, Zarezadeh M, Dehghani A, et al. A systematic review and meta-analysis on the impact of oral vitamin E supplementation on apolipoproteins A1 and B100. Clin Nutr ESPEN. 2021;46:106-114doi: 10.1016/j.clnesp.2021.09.013.
Hamedi-Kalajahi, F., Zarezadeh, M., Dehghani, A., Musazadeh, V., Kolahi, A., Shabbidar, S., & Djafarian, K. (2021). A systematic review and meta-analysis on the impact of oral vitamin E supplementation on apolipoproteins A1 and B100. Clinical nutrition ESPEN, 46106-114. https://doi.org/10.1016/j.clnesp.2021.09.013
Hamedi-Kalajahi, Fateme, et al. "A systematic review and meta-analysis on the impact of oral vitamin E supplementation on apolipoproteins A1 and B100." Clinical nutrition ESPEN vol. 46 (2021): 106-114. doi: https://doi.org/10.1016/j.clnesp.2021.09.013
Hamedi-Kalajahi F, Zarezadeh M, Dehghani A, Musazadeh V, Kolahi A, Shabbidar S, Djafarian K. A systematic review and meta-analysis on the impact of oral vitamin E supplementation on apolipoproteins A1 and B100. Clin Nutr ESPEN. 2021 Dec;46:106-114. doi: 10.1016/j.clnesp.2021.09.013. Epub 2021 Sep 29. PMID: 34857183.
Copy Download .nbib Format: NLM
Temperature-Responsive Nanoparticles Enable Specific Binding of Apolipoproteins from Human Plasma.

Small (Weinheim an der Bergstrasse, Germany)

Prawatborisut M, Oberländer J, Jiang S, Graf R, Avlasevich Y, Morsbach S, Crespy D, Mailänder V, Landfester K.
PMID: 34761508
Small. 2021 Nov 10;e2103138. doi: 10.1002/smll.202103138. Epub 2021 Nov 10.

Apolipoproteins are an important class of proteins because they provide a so-called stealth effect to nanoparticles. The stealth effect on nanocarriers leads to a reduced unspecific uptake into immune cells and thereby to a prolonged blood circulation time. Herein,...

Cite
Prawatborisut M, Oberländer J, Jiang S, et al. Temperature-Responsive Nanoparticles Enable Specific Binding of Apolipoproteins from Human Plasma. Small. 2021;e2103138doi: 10.1002/smll.202103138.
Prawatborisut, M., Oberländer, J., Jiang, S., Graf, R., Avlasevich, Y., Morsbach, S., Crespy, D., Mailänder, V., & Landfester, K. (2021). Temperature-Responsive Nanoparticles Enable Specific Binding of Apolipoproteins from Human Plasma. Small (Weinheim an der Bergstrasse, Germany), e2103138. https://doi.org/10.1002/smll.202103138
Prawatborisut, Mongkhol, et al. "Temperature-Responsive Nanoparticles Enable Specific Binding of Apolipoproteins from Human Plasma." Small (Weinheim an der Bergstrasse, Germany) vol. (2021): e2103138. doi: https://doi.org/10.1002/smll.202103138
Prawatborisut M, Oberländer J, Jiang S, Graf R, Avlasevich Y, Morsbach S, Crespy D, Mailänder V, Landfester K. Temperature-Responsive Nanoparticles Enable Specific Binding of Apolipoproteins from Human Plasma. Small. 2021 Nov 10;e2103138. doi: 10.1002/smll.202103138. Epub 2021 Nov 10. PMID: 34761508.
Copy Download .nbib Format: NLM
Sodium salicylate rewires hepatic metabolic pathways in obesity and attenuates IL-1β secretion from adipose tissue: The implications for obesity-impaired reverse cholesterol transport.

Molecular metabolism

Kajani S, Curley S, O'Reilly ME, Yin X, Dillon ET, Guo W, Nilaweera KN, Brennan L, Roche HM, McGillicuddy FC.
PMID: 34954383
Mol Metab. 2021 Dec 24;101425. doi: 10.1016/j.molmet.2021.101425. Epub 2021 Dec 24.

INTRODUCTION: High-fat diet (HFD)-induced obesity impairs clearance of cholesterol through the Reverse Cholesterol Transport (RCT) pathway, with downregulation in hepatic expression of cholesterol and bile acid transporters, namely ABCG5/8 and ABCB11, and reduced high-density lipoprotein (HDL) cholesterol efflux capacity...

Cite
Kajani S, Curley S, O'Reilly ME, et al. Sodium salicylate rewires hepatic metabolic pathways in obesity and attenuates IL-1β secretion from adipose tissue: The implications for obesity-impaired reverse cholesterol transport. Mol Metab. 2021;101425doi: 10.1016/j.molmet.2021.101425.
Kajani, S., Curley, S., O'Reilly, M. E., Yin, X., Dillon, E. T., Guo, W., Nilaweera, K. N., Brennan, L., Roche, H. M., & McGillicuddy, F. C. (2021). Sodium salicylate rewires hepatic metabolic pathways in obesity and attenuates IL-1β secretion from adipose tissue: The implications for obesity-impaired reverse cholesterol transport. Molecular metabolism, 101425. https://doi.org/10.1016/j.molmet.2021.101425
Kajani, Sarina, et al. "Sodium salicylate rewires hepatic metabolic pathways in obesity and attenuates IL-1β secretion from adipose tissue: The implications for obesity-impaired reverse cholesterol transport." Molecular metabolism vol. (2021): 101425. doi: https://doi.org/10.1016/j.molmet.2021.101425
Kajani S, Curley S, O'Reilly ME, Yin X, Dillon ET, Guo W, Nilaweera KN, Brennan L, Roche HM, McGillicuddy FC. Sodium salicylate rewires hepatic metabolic pathways in obesity and attenuates IL-1β secretion from adipose tissue: The implications for obesity-impaired reverse cholesterol transport. Mol Metab. 2021 Dec 24;101425. doi: 10.1016/j.molmet.2021.101425. Epub 2021 Dec 24. PMID: 34954383.
Copy Download .nbib Format: NLM
Apolipoprotein F concentration, activity, and the properties of LDL controlling ApoF activation in hyperlipidemic plasma.

Journal of lipid research

Morton RE, Mihna D.
PMID: 35016907
J Lipid Res. 2022 Jan 08;100166. doi: 10.1016/j.jlr.2021.100166. Epub 2022 Jan 08.

Apolipoprotein F (ApoF) modulates lipoprotein metabolism by selectively inhibiting cholesteryl ester transfer protein (CETP) activity on LDL. This ApoF activity requires that it is bound to LDL. How hyperlipidemia alters total plasma ApoF and its binding to LDL are...

Cite
Morton RE, Mihna D. Apolipoprotein F concentration, activity, and the properties of LDL controlling ApoF activation in hyperlipidemic plasma. J Lipid Res. 2022;100166doi: 10.1016/j.jlr.2021.100166.
Morton, R. E., & Mihna, D. (2022). Apolipoprotein F concentration, activity, and the properties of LDL controlling ApoF activation in hyperlipidemic plasma. Journal of lipid research, 100166. https://doi.org/10.1016/j.jlr.2021.100166
Morton, Richard E, and Mihna, Daniel. "Apolipoprotein F concentration, activity, and the properties of LDL controlling ApoF activation in hyperlipidemic plasma." Journal of lipid research vol. (2022): 100166. doi: https://doi.org/10.1016/j.jlr.2021.100166
Morton RE, Mihna D. Apolipoprotein F concentration, activity, and the properties of LDL controlling ApoF activation in hyperlipidemic plasma. J Lipid Res. 2022 Jan 08;100166. doi: 10.1016/j.jlr.2021.100166. Epub 2022 Jan 08. PMID: 35016907.
Copy Download .nbib Format: NLM
Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis.

Journal of neurology, neurosurgery, and psychiatry

Thompson AG, Talbot K, Turner MR.
PMID: 34518331
J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):75-81. doi: 10.1136/jnnp-2021-327133. Epub 2021 Sep 13.

BACKGROUND: Premorbid body mass index, physical activity, diabetes and cardiovascular disease have been associated with an altered risk of developing amyotrophic lateral sclerosis (ALS). There is evidence of shared genetic risk between ALS and lipid metabolism. A very large...

Cite
Thompson AG, Talbot K, Turner MR. Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;93(1):75-81doi: 10.1136/jnnp-2021-327133.
Thompson, A. G., Talbot, K., & Turner, M. R. (2022). Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. Journal of neurology, neurosurgery, and psychiatry, 93(1), 75-81. https://doi.org/10.1136/jnnp-2021-327133
Thompson, Alexander G, et al. "Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis." Journal of neurology, neurosurgery, and psychiatry vol. 93,1 (2022): 75-81. doi: https://doi.org/10.1136/jnnp-2021-327133
Thompson AG, Talbot K, Turner MR. Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):75-81. doi: 10.1136/jnnp-2021-327133. Epub 2021 Sep 13. PMID: 34518331.
Copy Download .nbib Format: NLM
Importance of Apolipoprotein A-I and A-II Composition in HDL and Its Potential for Studying COVID-19 and SARS-CoV-2.

Medicines (Basel, Switzerland)

Cho KH.
PMID: 34357154
Medicines (Basel). 2021 Jul 16;8(7). doi: 10.3390/medicines8070038.

The composition and properties of apolipoprotein (apo) A-I and apoA-II in high-density lipoproteins (HDL) might be critical to SARS-CoV-2 infection via SR-BI and antiviral activity against COVID-19. HDL containing native apoA-I showed potent antiviral activity, while HDL containing glycated...

Cite
Cho KH. Importance of Apolipoprotein A-I and A-II Composition in HDL and Its Potential for Studying COVID-19 and SARS-CoV-2. Medicines (Basel). 2021;8(7)doi: 10.3390/medicines8070038.
Cho, K. H. (2021). Importance of Apolipoprotein A-I and A-II Composition in HDL and Its Potential for Studying COVID-19 and SARS-CoV-2. Medicines (Basel, Switzerland), 8(7), . https://doi.org/10.3390/medicines8070038
Cho, Kyung-Hyun. "Importance of Apolipoprotein A-I and A-II Composition in HDL and Its Potential for Studying COVID-19 and SARS-CoV-2." Medicines (Basel, Switzerland) vol. 8,7 (2021). doi: https://doi.org/10.3390/medicines8070038
Cho KH. Importance of Apolipoprotein A-I and A-II Composition in HDL and Its Potential for Studying COVID-19 and SARS-CoV-2. Medicines (Basel). 2021 Jul 16;8(7). doi: 10.3390/medicines8070038. PMID: 34357154; PMCID: PMC8307872.
Copy Download .nbib Format: NLM
Serum Amyloid A Is Present in Human Saccular Intracranial Aneurysm Walls and Associates With Aneurysm Rupture.

Journal of neuropathology and experimental neurology

Huuska N, Netti E, Tulamo R, Lehti S, Jahromi BR, Kovanen PT, Niemelä M.
PMID: 34534311
J Neuropathol Exp Neurol. 2021 Oct 26;80(10):966-974. doi: 10.1093/jnen/nlab086.

Saccular intracranial aneurysm (sIA) rupture leads to a disabling subarachnoid hemorrhage. Chronic inflammation and lipid accumulation in the sIA wall contribute to wall degenerative remodeling that precedes its rupture. A better understanding of the pathobiological process is essential for...

Cite
Huuska N, Netti E, Tulamo R, et al. Serum Amyloid A Is Present in Human Saccular Intracranial Aneurysm Walls and Associates With Aneurysm Rupture. J Neuropathol Exp Neurol. 2021;80(10):966-974doi: 10.1093/jnen/nlab086.
Huuska, N., Netti, E., Tulamo, R., Lehti, S., Jahromi, B. R., Kovanen, P. T., & Niemelä, M. (2021). Serum Amyloid A Is Present in Human Saccular Intracranial Aneurysm Walls and Associates With Aneurysm Rupture. Journal of neuropathology and experimental neurology, 80(10), 966-974. https://doi.org/10.1093/jnen/nlab086
Huuska, Nora, et al. "Serum Amyloid A Is Present in Human Saccular Intracranial Aneurysm Walls and Associates With Aneurysm Rupture." Journal of neuropathology and experimental neurology vol. 80,10 (2021): 966-974. doi: https://doi.org/10.1093/jnen/nlab086
Huuska N, Netti E, Tulamo R, Lehti S, Jahromi BR, Kovanen PT, Niemelä M. Serum Amyloid A Is Present in Human Saccular Intracranial Aneurysm Walls and Associates With Aneurysm Rupture. J Neuropathol Exp Neurol. 2021 Oct 26;80(10):966-974. doi: 10.1093/jnen/nlab086. PMID: 34534311.
Copy Download .nbib Format: NLM
The bidirectional link between HDL and COVID-19 infections.

Journal of lipid research

Feingold KR.
PMID: 33741421
J Lipid Res. 2021 Mar 17;62:100067. doi: 10.1016/j.jlr.2021.100067. Epub 2021 Mar 17.

No abstract available.

Cite
Feingold KR. The bidirectional link between HDL and COVID-19 infections. J Lipid Res. 2021;62:100067doi: 10.1016/j.jlr.2021.100067.
Feingold, K. R. (2021). The bidirectional link between HDL and COVID-19 infections. Journal of lipid research, 62100067. https://doi.org/10.1016/j.jlr.2021.100067
Feingold, Kenneth R. "The bidirectional link between HDL and COVID-19 infections." Journal of lipid research vol. 62 (2021): 100067. doi: https://doi.org/10.1016/j.jlr.2021.100067
Feingold KR. The bidirectional link between HDL and COVID-19 infections. J Lipid Res. 2021 Mar 17;62:100067. doi: 10.1016/j.jlr.2021.100067. Epub 2021 Mar 17. PMID: 33741421; PMCID: PMC7963524.
Copy Download .nbib Format: NLM
Showing 385 to 396 of 396 entries